;PMID: 11007037
;source_file_571.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..32] = [t:0..32]
;1)sentence:[e:37..96] = [t:37..96]
;2)section:[e:100..206] = [t:100..206]
;3)section:[e:210..356] = [t:210..356]
;4)sentence:[e:360..540] = [t:360..540]
;5)sentence:[e:541..811] = [t:541..811]
;6)sentence:[e:812..1099] = [t:812..1099]
;7)sentence:[e:1100..1282] = [t:1100..1282]
;8)sentence:[e:1283..1352] = [t:1283..1352]
;9)sentence:[e:1353..1468] = [t:1353..1468]
;10)sentence:[e:1470..1521] = [t:1470..1521]
;11)sentence:[e:1522..1572] = [t:1522..1572]
;12)sentence:[e:1573..1693] = [t:1573..1693]
;13)sentence:[e:1694..1774] = [t:1694..1774]
;14)section:[e:1778..1823] = [t:1778..1823]

;section 0 Span:0..32
;Mod Pathol  2000 Sep;13(9):973-7
(SEC
  (FRAG (DT:[0..3] Mod) (NNP:[4..10] Pathol) (CD:[12..16] 2000)
        (.:[17..24] Sep;13-LRB-) (CD:[24..25] 9) (-RRB-:[25..26] -RRB-)
        (CD:[26..30] :973) (::[30..31] -) (CD:[31..32] 7)))

;sentence 1 Span:37..96
;Missense mutation of the MET gene detected in human glioma.
;[37..54]:variation-type:"Missense mutation"
;[62..65]:gene-rna:"MET"
;[89..95]:malignancy:"glioma"
(SENT
  (NP-HLN
    (NP
      (NP (JJ:[37..45] Missense) (NN:[46..54] mutation))
      (PP (IN:[55..57] of)
        (NP (DT:[58..61] the) (NN:[62..65] MET) (NN:[66..70] gene))))
    (VP (VBN:[71..79] detected)
      (NP (-NONE-:[79..79] *))
      (PP (IN:[80..82] in)
        (NP (JJ:[83..88] human) (NN:[89..95] glioma))))
    (.:[95..96] .)))

;section 2 Span:100..206
;Moon YW, Weil RJ, Pack SD, Park WS, Pak E, Pham T, Karkera JD, Kim HK,
;Vortmeyer  AO, Fuller BG, Zhuang Z.
(SEC
  (FRAG (NNP:[100..104] Moon) (NNP:[105..107] YW) (,:[107..108] ,)
        (NNP:[109..113] Weil) (NNP:[114..116] RJ) (,:[116..117] ,)
        (NNP:[118..122] Pack) (NNP:[123..125] SD) (,:[125..126] ,)
        (NNP:[127..131] Park) (NNP:[132..134] WS) (,:[134..135] ,)
        (NNP:[136..139] Pak) (NNP:[140..141] E) (,:[141..142] ,)
        (NNP:[143..147] Pham) (NNP:[148..149] T) (,:[149..150] ,)
        (NNP:[151..158] Karkera) (NNP:[159..161] JD) (,:[161..162] ,)
        (NNP:[163..166] Kim) (NNP:[167..169] HK) (,:[169..170] ,)
        (NNP:[171..180] Vortmeyer) (NNP:[182..184] AO) (,:[184..185] ,)
        (NNP:[186..192] Fuller) (NNP:[193..195] BG) (,:[195..196] ,)
        (NNP:[197..203] Zhuang) (NNP:[204..205] Z) (.:[205..206] .)))

;section 3 Span:210..356
;Radiation Oncology Branch, National Institute of Neurological Disorders and 
;Stroke, National Institutes of Health, Bethesda, Maryland 20892, USA.
(SEC
  (FRAG (NNP:[210..219] Radiation) (NNP:[220..228] Oncology)
        (NNP:[229..235] Branch) (,:[235..236] ,) (NNP:[237..245] National)
        (NNP:[246..255] Institute) (IN:[256..258] of)
        (NNP:[259..271] Neurological) (NNP:[272..281] Disorders)
        (CC:[282..285] and) (NNP:[287..293] Stroke) (,:[293..294] ,)
        (NNP:[295..303] National) (NNPS:[304..314] Institutes)
        (IN:[315..317] of) (NNP:[318..324] Health) (,:[324..325] ,)
        (NNP:[326..334] Bethesda) (,:[334..335] ,) (NNP:[336..344] Maryland)
        (VBZ:[345..350] 20892) (NNP:[350..351] ,) (NNP:[352..355] USA)
        (.:[355..356] .)))

;sentence 4 Span:360..540
;Multiple mechanisms, such as gene mutations, amplifications, and
;rearrangements,  as well as perturbed mitogen and receptor function, are
;likely to contribute to  glioma formation.
;[405..419]:variation-type:"amplifications"
;[425..439]:variation-type:"rearrangements"
;[523..529]:malignancy:"glioma"
(SENT
  (S
    (NP-SBJ-4
      (NP (JJ:[360..368] Multiple) (NNS:[369..379] mechanisms))
      (,:[379..380] ,)
      (PP (JJ:[381..385] such) (IN:[386..388] as)
        (NP
          (NP
            (NP
              (NML-3 (NN:[389..393] gene))
              (NNS:[394..403] mutations))
            (,:[403..404] ,)
            (NP
              (NML-3 (-NONE-:[404..404] *P*))
              (NNS:[405..419] amplifications))
            (,:[419..420] ,) (CC:[421..424] and)
            (NP
              (NML-3 (-NONE-:[424..424] *P*))
              (NNS:[425..439] rearrangements)))
          (,:[439..440] ,)
          (CONJP (RB:[442..444] as) (RB:[445..449] well) (IN:[450..452] as))
          (NP
            (NP
              (ADJP-2 (JJ:[453..462] perturbed))
              (NN:[463..470] mitogen)
              (NML-1 (-NONE-:[470..470] *P*)))
            (CC:[471..474] and)
            (NP
              (ADJP-2 (-NONE-:[474..474] *P*))
              (NN:[475..483] receptor)
              (NML-1 (NN:[484..492] function)))))))
    (,:[492..493] ,)
    (VP (VBP:[494..497] are)
      (ADJP-PRD (JJ:[498..504] likely)
        (S
          (NP-SBJ-4 (-NONE-:[504..504] *))
          (VP (TO:[505..507] to)
            (VP (VB:[508..518] contribute)
              (PP-CLR (TO:[519..521] to)
                (NP (NN:[523..529] glioma) (NN:[530..539] formation))))))))
    (.:[539..540] .)))

;sentence 5 Span:541..811
;The MET (also known as c-met proto-oncogene located at 7q31-34  has been
;shown to be amplified in human gliomas, and activating mutations within  the
;tyrosine kinase domain of MET have been causally related to tumorigenesis in 
;hereditary papillary renal cell carcinoma.
;[545..548]:gene-rna:"MET"
;[564..569]:gene-rna:"c-met"
;[596..603]:variation-location:"7q31-34"
;[645..652]:malignancy:"gliomas"
;[669..678]:variation-event:"mutations"
;[691..706]:gene-protein:"tyrosine kinase"
;[717..720]:gene-rna:"MET"
;[769..810]:malignancy:"hereditary papillary renal cell carcinoma"
(SENT
  (S
    (S
      (NP-SBJ-2
        (NP (DT:[541..544] The) (NN:[545..548] MET)
          (PRN (-LRB-:[549..550] -LRB-)
            (VP
              (ADVP (RB:[550..554] also))
              (VBN:[555..560] known)
              (NP (-NONE-:[560..560] *))
              (PP (IN:[561..563] as)
                (NP (NN:[564..569] c-met)))))
          (AFX:[570..575] proto) (HYPH:[575..576] -) (NN:[576..584] oncogene))
        (VP (VBN:[585..592] located)
          (NP (-NONE-:[592..592] *))
          (PP-LOC (IN:[593..595] at)
            (NP (NN:[596..600] 7q31) (HYPH:[600..601] -) (CD:[601..603] 34)))))
      (VP (VBZ:[605..608] has)
        (VP (VBN:[609..613] been)
          (VP (VBN:[614..619] shown)
            (S
              (NP-SBJ-2 (-NONE-:[619..619] *))
              (VP (TO:[620..622] to)
                (VP (VB:[623..625] be)
                  (VP (VBN:[626..635] amplified)
                    (NP-2 (-NONE-:[635..635] *))
                    (PP-LOC (IN:[636..638] in)
                      (NP (JJ:[639..644] human) (NNS:[645..652] gliomas)))))))))))
    (,:[652..653] ,) (CC:[654..657] and)
    (S
      (NP-SBJ-1
        (NP (VBG:[658..668] activating) (NNS:[669..678] mutations))
        (PP (IN:[679..685] within)
          (NP
            (NP (DT:[687..690] the)
              (NML (NN:[691..699] tyrosine) (NN:[700..706] kinase))
              (NN:[707..713] domain))
            (PP (IN:[714..716] of)
              (NP (NN:[717..720] MET))))))
      (VP (VBP:[721..725] have)
        (VP (VBN:[726..730] been)
          (ADVP (RB:[731..739] causally))
          (VP (VBN:[740..747] related)
            (NP-1 (-NONE-:[747..747] *))
            (PP-CLR (TO:[748..750] to)
              (NP
                (NP (NN:[751..764] tumorigenesis))
                (PP (IN:[765..767] in)
                  (NP (JJ:[769..779] hereditary) (JJ:[780..789] papillary)
                    (NML (JJ:[790..795] renal) (NN:[796..800] cell))
                    (NN:[801..810] carcinoma)))))))))
    (.:[810..811] .)))

;sentence 6 Span:812..1099
;To elucidate the role of MET gene in  glioma formation, sporadic gliomas from
;11 patients were examined for MET gene  mutations and allelic duplications or
;deletions by polymerase chain  reaction-single strand conformational
;polymorphism analysis and fluorescence in  situ hybridization.
;[837..840]:gene-rna:"MET"
;[850..856]:malignancy:"glioma"
;[868..884]:malignancy:"sporadic gliomas"
;[920..923]:gene-rna:"MET"
;[944..964]:variation-type:"allelic duplications"
;[968..977]:variation-type:"deletions"
;[981..991]:gene-protein:"polymerase"
(SENT
  (S
    (S-PRP
      (NP-SBJ (-NONE-:[812..812] *))
      (VP (TO:[812..814] To)
        (VP (VB:[815..824] elucidate)
          (NP
            (NP (DT:[825..828] the) (NN:[829..833] role))
            (PP (IN:[834..836] of)
              (NP (NN:[837..840] MET) (NN:[841..845] gene))))
          (PP (IN:[846..848] in)
            (NP (NN:[850..856] glioma) (NN:[857..866] formation))))))
    (,:[866..867] ,)
    (NP-SBJ-2
      (NP (JJ:[868..876] sporadic) (NNS:[877..884] gliomas))
      (PP (IN:[885..889] from)
        (NP (CD:[890..892] 11) (NNS:[893..901] patients))))
    (VP (VBD:[902..906] were)
      (VP (VBN:[907..915] examined)
        (NP-2 (-NONE-:[915..915] *))
        (PP (IN:[916..919] for)
          (NP
            (NP (NN:[920..923] MET) (NN:[924..928] gene)
                (NNS:[930..939] mutations))
            (CC:[940..943] and)
            (NP
              (NP
                (ADJP-1 (JJ:[944..951] allelic))
                (NNS:[952..964] duplications))
              (CC:[965..967] or)
              (NP
                (ADJP-1 (-NONE-:[967..967] *P*))
                (NNS:[968..977] deletions)))))
        (PP-MNR (IN:[978..980] by)
          (NP
            (NP
              (NML
                (NML (NN:[981..991] polymerase) (NN:[992..997] chain)
                     (NN:[999..1007] reaction))
                (HYPH:[1007..1008] -)
                (NML
                  (NML (JJ:[1008..1014] single) (NN:[1015..1021] strand))
                  (JJ:[1022..1036] conformational)
                   (JJ:[1037..1049] polymorphism)))
              (NN:[1050..1058] analysis))
            (CC:[1059..1062] and)
            (NP (NN:[1063..1075] fluorescence)
              (NML (FW:[1076..1078] in) (FW:[1080..1084] situ))
              (NN:[1085..1098] hybridization))))))
    (.:[1098..1099] .)))

;sentence 7 Span:1100..1282
;Three of 11 sporadic gliomas showed a deletion of one copy  of the MET gene,
;and a specific METgene missense mutation in the remaining gene  copy was
;detected in one of those tumors.
;[1112..1128]:malignancy:"sporadic gliomas"
;[1138..1146]:variation-type:"deletion"
;[1167..1170]:gene-rna:"MET"
;[1192..1195]:gene-rna:"MET"
;[1200..1217]:variation-type:"missense mutation"
;[1275..1281]:malignancy:"tumors"
(SENT
  (S
    (S
      (NP-SBJ
        (NP (CD:[1100..1105] Three))
        (PP (IN:[1106..1108] of)
          (NP (CD:[1109..1111] 11)
             (JJ:[1112..1120] sporadic) (NNS:[1121..1128] gliomas))))
      (VP (VBD:[1129..1135] showed)
        (NP
          (NP (DT:[1136..1137] a) (NN:[1138..1146] deletion))
          (PP (IN:[1147..1149] of)
            (NP
              (NP (CD:[1150..1153] one) (NN:[1154..1158] copy))
              (PP (IN:[1160..1162] of)
                (NP (DT:[1163..1166] the) (NN:[1167..1170] MET)
                    (NN:[1171..1175] gene))))))))
    (,:[1175..1176] ,) (CC:[1177..1180] and)
    (S
      (NP-SBJ-1
        (NP (DT:[1181..1182] a) (JJ:[1183..1191] specific)
          (NML (NN:[1192..1195] MET) (NN:[1195..1199] gene))
           (JJ:[1200..1208] missense) (NN:[1209..1217] mutation))
        (PP-LOC (IN:[1218..1220] in)
          (NP (DT:[1221..1224] the) (VBG:[1225..1234] remaining)
              (NN:[1235..1239] gene) (NN:[1241..1245] copy))))
      (VP (VBD:[1246..1249] was)
        (VP (VBN:[1250..1258] detected)
          (NP-1 (-NONE-:[1258..1258] *))
          (PP-LOC (IN:[1259..1261] in)
            (NP
              (NP (CD:[1262..1265] one))
              (PP (IN:[1266..1268] of)
                (NP (DT:[1269..1274] those) (NNS:[1275..1281] tumors))))))))
    (.:[1281..1282] .)))

;sentence 8 Span:1283..1352
;The corresponding sequence in  non-tumor DNA was normal in all cases.
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1283..1286] The) (VBG:[1287..1300] corresponding)
          (NN:[1301..1309] sequence))
      (PP (IN:[1310..1312] in)
        (NP
          (NML (AFX:[1314..1317] non) (HYPH:[1317..1318] -)
               (NN:[1318..1323] tumor))
          (NN:[1324..1327] DNA))))
    (VP (VBD:[1328..1331] was)
      (NP-PRD (JJ:[1332..1338] normal)
        (PP (IN:[1339..1341] in)
          (NP (DT:[1342..1345] all) (NNS:[1346..1351] cases)))))
    (.:[1351..1352] .)))

;sentence 9 Span:1353..1468
;Three of 11 sporadic gliomas showed  duplication of one copy of the MET gene,
;but none of them contained mutations.
;[1365..1381]:malignancy:"sporadic gliomas"
;[1421..1424]:gene-rna:"MET"
;[1458..1467]:variation-event:"mutations"
(SENT
  (S
    (S
      (NP-SBJ
        (NP (CD:[1353..1358] Three))
        (PP (IN:[1359..1361] of)
          (NP (CD:[1362..1364] 11)
             (JJ:[1365..1373] sporadic) (NNS:[1374..1381] gliomas))))
      (VP (VBD:[1382..1388] showed)
        (NP
          (NP (NN:[1390..1401] duplication))
          (PP (IN:[1402..1404] of)
            (NP
              (NP (CD:[1405..1408] one) (NN:[1409..1413] copy))
              (PP (IN:[1414..1416] of)
                (NP (DT:[1417..1420] the) (NN:[1421..1424] MET)
                    (NN:[1425..1429] gene))))))))
    (,:[1429..1430] ,) (CC:[1431..1434] but)
    (S
      (NP-SBJ
        (NP (NN:[1435..1439] none))
        (PP (IN:[1440..1442] of)
          (NP (PRP:[1443..1447] them))))
      (VP (VBD:[1448..1457] contained)
        (NP (NNS:[1458..1467] mutations))))
    (.:[1467..1468] .)))

;sentence 10 Span:1470..1521
;One tumor showed METamplification without mutation.
;[1474..1479]:malignancy:"tumor"
;[1487..1490]:gene-rna:"MET"
;[1512..1520]:variation-event:"mutation"
(SENT
  (S
    (NP-SBJ (CD:[1470..1473] One) (NN:[1474..1479] tumor))
    (VP (VBD:[1480..1486] showed)
      (NP
        (NP (NN:[1487..1490] MET) (NN:[1490..1503] amplification))
        (PP (IN:[1504..1511] without)
          (NP (NN:[1512..1520] mutation)))))
    (.:[1520..1521] .)))

;sentence 11 Span:1522..1572
;Three showed neither allelic  change nor mutation.
;[1563..1571]:variation-event:"mutation"
(SENT
  (S
    (NP-SBJ (CD:[1522..1527] Three))
    (VP (VBD:[1528..1534] showed)
      (NP (CC:[1535..1542] neither)
        (NP (JJ:[1543..1550] allelic) (NN:[1552..1558] change))
        (CC:[1559..1562] nor)
        (NP (NN:[1563..1571] mutation))))
    (.:[1571..1572] .)))

;sentence 12 Span:1573..1693
;These data suggest that somatic MET gene mutation may play  a role in the
;development of a subgroup of sporadic gliomas.
;[1605..1608]:gene-rna:"MET"
;[1676..1692]:malignancy:"sporadic gliomas"
(SENT
  (S
    (NP-SBJ (DT:[1573..1578] These) (NNS:[1579..1583] data))
    (VP (VBP:[1584..1591] suggest)
      (SBAR (IN:[1592..1596] that)
        (S
          (NP-SBJ (JJ:[1597..1604] somatic)
            (NML (NN:[1605..1608] MET) (NN:[1609..1613] gene))
            (NN:[1614..1622] mutation))
          (VP (MD:[1623..1626] may)
            (VP (VB:[1627..1631] play)
              (NP (DT:[1633..1634] a) (NN:[1635..1639] role))
              (PP (IN:[1640..1642] in)
                (NP
                  (NP (DT:[1643..1646] the) (NN:[1647..1658] development))
                  (PP (IN:[1659..1661] of)
                    (NP
                      (NP (DT:[1662..1663] a) (NN:[1664..1672] subgroup))
                      (PP (IN:[1673..1675] of)
                        (NP (JJ:[1676..1684] sporadic)
                            (NNS:[1685..1692] gliomas))))))))))))
    (.:[1692..1693] .)))

;sentence 13 Span:1694..1774
;However, MET  mutations appear to be absent in the majority of sporadic
;gliomas.
;[1703..1706]:gene-rna:"MET"
;[1757..1773]:malignancy:"sporadic gliomas"
(SENT
  (S
    (ADVP (RB:[1694..1701] However))
    (,:[1701..1702] ,)
    (NP-SBJ-1 (NN:[1703..1706] MET) (NNS:[1708..1717] mutations))
    (VP (VBP:[1718..1724] appear)
      (S
        (NP-SBJ-1 (-NONE-:[1724..1724] *))
        (VP (TO:[1725..1727] to)
          (VP (VB:[1728..1730] be)
            (ADJP-PRD (JJ:[1731..1737] absent)
              (PP (IN:[1738..1740] in)
                (NP
                  (NP (DT:[1741..1744] the) (NN:[1745..1753] majority))
                  (PP (IN:[1754..1756] of)
                    (NP (JJ:[1757..1765] sporadic) (NNS:[1766..1773] gliomas))))))))))
    (.:[1773..1774] .)))

;section 14 Span:1778..1823
;PMID: 11007037 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1778..1782] PMID) (::[1782..1783] :) (CD:[1784..1792] 11007037)
        (NN:[1793..1794] -LSB-) (NNP:[1794..1800] PubMed) (::[1801..1802] -)
        (NN:[1803..1810] indexed) (IN:[1811..1814] for)
        (NNP:[1815..1823] MEDLINE-RSB-)))
